Results 41 to 50 of about 1,831 (172)

Tanshinone-I for the treatment of uterine fibroids: Molecular docking, simulation, and density functional theory investigations

Saudi Pharmaceutical Journal, 2023
Uterine fibroids (UF), most prevalent gynecological disorder, require surgery when symptomatic. It is estimated that between 25 and 35 percent of women wait until the symptoms have worsened like extended heavy menstrual bleeding and severe pelvic pain ...
Abhishek Tiwari, Varsha Tiwari, Ajay Sharma, Deependra Singh, Manju Singh Rawat, Tarun Virmani, Reshu Virmani, Girish Kumar, Manish Kumar, Abdulsalam Alhalmi, Omar M. Noman, Ramzi A. Mothana, Mohammad Alali   +12 more
doaj   +1 more source

Efficacy of hormonal therapies for decreasing uterine volume in patients with adenomyosis

Gynecology and Minimally Invasive Therapy, 2018
Study objective: The aim of this study is to evaluate the efficacy of hormonal therapies for inhibiting an increase in uterine volume in patients with adenomyosis. Design: This was retrospective cohort study.
Takashi Matsushima, Shigeo Akira, Takehiko Fukami, Koichi Yoneyama, Toshiyuki Takeshita   +4 more
doaj   +1 more source

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model

CPT: Pharmacometrics & Systems Pharmacology, 2020
Elagolix is an oral gonadotropin‐releasing hormone antagonist approved by the US Food and Drug Administration (FDA) for the management of moderate‐to‐severe pain associated with endometriosis and in combination with estradiol/norethindrone acetate ...
Insa Winzenborg, Akshanth R. Polepally, Ahmed Nader, Nael M. Mostafa, Peter Noertersheuser, Juki Ng   +5 more
doaj   +1 more source

Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis

F&S Reports, 2023
Treatment of uterine fibroids (UF) and endometriosis (EM) has relied on the surgical skills of gynecologists to improve symptoms and potentially alter the course of these debilitating diseases.
Juan C. Arjona Ferreira, M.D., Elizabeth Migoya, Pharm.D.   +1 more
doaj   +1 more source

Combined Continuous Ethinyl Estradiol/Norethindrone Acetate Does Not Improve Forearm Blood Flow in Postmenopausal Women at Risk for Cardiovascular Events: A Pilot Study [PDF]

, 2007
Objective: This study sought to determine whether combined continuous ethinyl estradiol and norethindrone acetate, a postmenopausal hormone therapy (HT) combination designed to have fewer side effects than cyclical therapies and therapies using ...
Rose, Patricia A., Brook, Robert D., Kehrer, Christine, Duvernoy, Claire S., Kim, H. Myra   +4 more
core   +1 more source

Colorimetric Analysis of Norethindrone, Norethindrone Acetate, and Norgestrel in Oral Contraceptives

Journal of AOAC INTERNATIONAL, 1970
Abstract A colorimetric method, based on reaction with blue tetrazolium, has been devised for the analysis of norethindrone, norethindrone acetate, and norgestrel. The technique is selective for these progestins, showing no interference from the estrogens ethinyl estradiol and mestranol, commonly found in oral contraceptives.
Shuing Carol Liu, Thomas H Hassall, Robert V Smith   +2 more
openaire   +1 more source

Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate

, 2005
Objective: To evaluate the efficacy, safety, and tolerability of an estrogen-progestogen combination versus low-dose norethindrone acetate in the treatment of persistent pain after surgery for symptomatic rectovaginal endometriosis.
O. De Giorgi, G. Pietropaolo, P.G. Crosignani, R. Pasin, P. Vercellini, A. Chiodini   +5 more
core   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Formation of Ethinyl Estradiol in Women during Treatment with Norethindrone Acetate [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2007
The significance of the conversion of norethindrone acetate (NET-A), a commonly prescribed, synthetic, oral progestogen, to ethinyl estradiol (EE(2)) is controversial.We sought to determine accurately the extent to which NET-A may be converted to EE(2), and if so, whether circulating levels of EE(2) would be of clinical significance.
Micheline C, Chu, Xiaohua, Zhang, Elisabet, Gentzschein, Frank Z, Stanczyk, Rogerio A, Lobo   +4 more
openaire   +2 more sources

Bioequivalence of a Fixed‐Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open‐Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions

Clinical Pharmacology in Drug Development, Volume 15, Issue 6, June 2026.
Abstract Uterine fibroids are the most common benign gynecological tumors, often causing heavy menstrual bleeding (HMB), anemia, and impaired quality of life. A fixed‐dose combination (FDC) of relugolix (40 mg), estradiol (1 mg), and norethindrone acetate (0.5 mg) was developed to address these limitations.
Ravi Kotadia, Sudershan Kumar, Arshad Khuroo, Shruti Dharmadhikari, Pradeep Shahi, Goru N. V. S. Satya Narayana, Simrit Reyar   +6 more
wiley   +1 more source